Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Principia Biopharma Inc.PRNB · Entity 146423 | Director · 10% owner | September 13, 2018 | September 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Principia Biopharma Inc.
Report date September 13, 2018 · Filed September 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
| Series B-2 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
| Series B-3 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
| Warrant to Purchase Series B-3 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.99 · Expires 2022-12-29 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2018-09-13 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F3: This warrant is exercisable at any time. F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
F2: The securities are held by Morgenthaler Venture Partners IX, L.P. ("MVP IX"). The General Partner of MVP IX is Morgenthaler Management Partners IX, LLC ("MMP IX"). MMP IX may be deemed to indirectly beneficially own the securities held directly by MVP IX. Reporting Person is a venture partner at MMP IX and may be deemed to have an indirect pecuniary interest in these shares. Reporting Person disclaims beneficial ownership of the shares held of record by MVP IX except to the extent of his pecuniary interest therein. Reporting Person does not have voting or dispositive power over the shares.
F3: This warrant is exercisable at any time.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GYRE THERAPEUTICS, INC.
Report date June 28, 2024 · Filed July 01, 2024
Section 16 reporting ended · disclosed 2024-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,636 |
Ending reported balance
After 2024-06-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-28 · Exercise / conversion · Acquired 3,452 · Balance 5,088 Row 2 · 2024-06-28 · Sale · Disposed 3,452 · Balance 1,636 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.025. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.93 · Expires 2033-10-31 | Direct | 278,200 |
Reported balance
After 2024-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-28 · Exercise / conversion · Disposed 3,452 · Balance 278,200 F3: This option is vested in full. |
| Common StockSEC Table I · non-derivative | IndirectBy The Usman Family Trust | 563 |
Reported balance
Holding disclosure · report date 2024-06-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 563 |
| Common StockSEC Table I · non-derivative | IndirectBy Nassim Usman IRA | 77 |
Reported balance
Holding disclosure · report date 2024-06-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 77 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.025. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: This option is vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2024 Filed Jul 1, 2024 22:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,452 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-24-032024 · form4.xml · derivative · entry 5 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,200 Underlying: Common Stock · 3,452 shares Expires 2033-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is vested in full. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 22:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 3,452 | $12.00 | $41,437.81 |
DisclosureSEC source: 0001140361-24-032024 · form4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.025. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 22:00 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 3,452 | $6.93 | $23,922.36 |
DisclosureSEC source: 0001140361-24-032024 · form4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-24-024125 · form4.xml · derivative · entry 7 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,652 Underlying: Common Stock · 20,000 shares Expires 2033-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is vested in full. Read SEC document |
| May 01, 2024 Filed May 2, 2024 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 100 | $15.63 | $1,563.00 |
DisclosureSEC source: 0001140361-24-024125 · form4.xml · nonDerivative · entry 4 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. Read SEC document |
| May 01, 2024 Filed May 2, 2024 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 5,000 | $14.90 | $74,500.00 |
DisclosureSEC source: 0001140361-24-024125 · form4.xml · nonDerivative · entry 3 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,736 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 2, 2024 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 14,900 | $13.86 | $206,514.00 |
DisclosureSEC source: 0001140361-24-024125 · form4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,736 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2024 Filed May 2, 2024 22:19 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 20,000 | $6.93 | $138,600.00 |
DisclosureSEC source: 0001140361-24-024125 · form4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-24-017566 · form4.xml · derivative · entry 5 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,652 Underlying: Common Stock · 20,000 shares Expires 2033-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is vested in full. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 20,000 | $16.15 | $323,000.00 |
DisclosureSEC source: 0001140361-24-017566 · form4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.80 to $17.15. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:01 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 20,000 | $6.93 | $138,600.00 |
DisclosureSEC source: 0001140361-24-017566 · form4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:47 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-24-014164 · form4.xml · derivative · entry 5 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,652 Underlying: Common Stock · 20,000 shares Expires 2033-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is vested in full. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:47 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | SaleCommon Stock | 20,000 | $17.26 | $345,200.00 |
DisclosureSEC source: 0001140361-24-014164 · form4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $16.07 to $18.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 20:47 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | Exercise / conversionCommon Stock | 20,000 | $6.93 | $138,600.00 |
DisclosureSEC source: 0001140361-24-014164 · form4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050616 · form4.xml · derivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2033-10-31 F2 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 341,652 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050616 · form4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,652 Underlying: Common Stock · 341,652 shares Expires 2033-10-31 F1 · derivative.exercise_date: These options are vested in full. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 1.168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042367 · form4.xml · nonDerivative · entry 3 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Nassim Usman IRA Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 8.456 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042367 · form4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By The Usman Family Trust Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 24.541 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042367 · form4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 21:19 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.47 | $1,527.50 |
DisclosureSEC source: 0001209191-22-045256 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,541 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 17, 2022 01:13 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,250 | $0.46 | $1,495.00 |
DisclosureSEC source: 0001209191-22-010407 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,291 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2022. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 13:15 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 867 | $3.62 | $3,138.54 |
DisclosureSEC source: 0001209191-21-050759 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,041 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 14:55 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-21-025783 · doc4.xml · derivative · entry 4 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,783 Underlying: Common Stock · 5,000 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 14:55 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 5,000 | $4.63 | $23,150.00 |
DisclosureSEC source: 0001209191-21-025783 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2021 Filed Feb 23, 2021 02:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 582 | $4.81 | $2,799.42 |
DisclosureSEC source: 0001209191-21-013037 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,174 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001209191-21-009355 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing February 8, 2021. Read SEC document |
| February 08, 2021 Filed Apr 26, 2021 21:39 UTC Amendment | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001209191-21-028358 · doc4a.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: Award vests and will become exercisable monthly over 48 months, with 25% of the shares vesting on the 12-month anniversary of the date hereof, and the remainder vesting monthly thereafter at the rate of 1/48th of the total number of shares. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:12 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 582 | $4.81 | $2,799.42 |
DisclosureSEC source: 0001209191-20-046348 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,592 F1 · shares: Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 10, 2020. Read SEC document |
| March 13, 2020 Filed Mar 13, 2020 22:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 4,000 | $3.91 | $15,647.20 |
DisclosureSEC source: 0001209191-20-019040 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,010 F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $3.87 to $3.92 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 01:28 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 430 | $6.23 | $2,678.90 |
DisclosureSEC source: 0001209191-20-009041 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 10, 2020. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 19:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001209191-20-004965 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2030-01-23 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing January 23, 2020. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 20:21 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 413 | $6.51 | $2,688.63 |
DisclosureSEC source: 0001209191-19-045504 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,580 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on August 12, 2019. Read SEC document |
| May 21, 2019 Filed May 22, 2019 18:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GiftCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031970 · doc4.xml · nonDerivative · entry 3 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Usman Family Trust Disclosed balance after: 8,456 F1 · balance_after: On May 21, 2019, the reporting person transferred 4,400 directly owned shares of Company common stock to the Usman Family Trust of which the insider and his wife are trustees and beneficiaries. Read SEC document |
| May 21, 2019 Filed May 22, 2019 18:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GiftCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031970 · doc4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,167 F1 · balance_after: On May 21, 2019, the reporting person transferred 4,400 directly owned shares of Company common stock to the Usman Family Trust of which the insider and his wife are trustees and beneficiaries. Read SEC document |
| May 21, 2019 Filed May 22, 2019 18:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 4,400 | $4.63 | $20,372.00 |
DisclosureSEC source: 0001209191-19-031970 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-19-031970 · doc4.xml · derivative · entry 5 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,783 Underlying: Common Stock · 4,400 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 22:01 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 350 | $7.04 | $2,464.00 |
DisclosureSEC source: 0001209191-19-009705 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,167 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 11, 2019. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,729 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-19-006857 · doc4.xml · derivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,271 Underlying: Common Stock · 5,729 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017 Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 21:51 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 5,729 | $4.63 | $26,525.27 |
DisclosureSEC source: 0001209191-19-006857 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 23:58 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0001209191-19-005668 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing January 24, 2019. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 21:48 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0001209191-18-044791 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-30 F1 · derivative.exercise_date: Award vests monthly over four (4) years starting June 13, 2018. Read SEC document |
| April 09, 2018 Filed Apr 12, 2018 00:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GiftCommon Stock | 88 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024695 · doc4.xml · nonDerivative · entry 2 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The Usman Family Trust Disclosed balance after: 4,144 F1 · balance_after: Reflects a 1:15 reverse stock split effected on February 10, 2017. Read SEC document |
| April 09, 2018 Filed Apr 12, 2018 00:00 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GiftCommon Stock | 88 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024695 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 21:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 88 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-024224 · doc4.xml · derivative · entry 4 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,912 Underlying: Common Stock · 88 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 21:03 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 88 | $4.63 | $407.44 |
DisclosureSEC source: 0001209191-18-024224 · doc4.xml · nonDerivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 20:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option(Right to Buy) · Derivative | 95,000 | $0.00 Strike: $15.13 | $0.00 |
DisclosureSEC source: 0000899243-18-001064 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-01-12 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing January 12, 2018. Read SEC document |
| July 11, 2017 Filed Jul 12, 2017 20:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-17-044899 · doc4.xml · derivative · entry 1 USMAN NASSIM · CIK 0001206872 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-07-11 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.